A growing disconnect is emerging between microbiome science and the booming consumer wellness market. A recent commentary in The New England Journal of Medicine argues that direct-to-consumer microbiome tests often produce inconsistent and conflicting results, with identical stool samples generating different microbial profiles, health scores, and supplement recommendations across companies.
While the microbiome remains one of the most promising frontiers in medicine, experts caution that current commercial testing lacks standardization, clinical validation, and consensus around what defines a “healthy” microbiome. The article also highlights concerns that many companies monetize uncertainty by pairing expensive testing with recurring supplement and probiotic sales, despite limited evidence that these personalized recommendations improve outcomes.